Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orantinib with TACE in Unresectable Hepatocellular Carcinoma
NCT01465464Phase 3Terminated
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of orantinib in hepatocellular carcinoma (HCC), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Dec 2010; status: terminated.
02
Drugs
orantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01465464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465464.